PFIZER INC

Pfizer’s 4% stock rally sparks concerns as a $1.2 billion Depo‑Provera settlement and a lagging R&D pipeline threaten the company’s high valuation and investor confidence.

Pfizer’s 2026 earnings reveal a 5% boost in non‑COVID sales, $9.7 B in cost‑savings, and a sharp focus on precision oncology to drive future growth.

Discover how Pfizer’s diversified portfolio and advanced therapeutics position it amid shifting tech‑driven market momentum and rising global drug demand.

Pfizer’s Q2 2026 earnings beat expectations with $15.03 bn revenue, lifts 2026 guidance, and signals resilience amid patent cliff pressures.

Pfizer’s Phase‑III win for Litfulo and EU approval of its updated COVID‑19 vaccine signal a new growth wave in dermatology and immunization, boosting investor confidence and shareholder returns.

Pfizer partners with Eisai to launch dual‑action migraine drug Nurtec in Japan, boosting revenue and market reach in the growing CGRP therapy space.

Pfizer wins FDA priority review for Talzenna + Xtandi, a dual‑mechanism therapy that could redefine first‑line treatment for metastatic prostate cancer.

Pfizer’s pivot from COVID‑EUA sales to booming oncology drives future growth, with analysts pointing to a $30.17 target and a robust pipeline.

Pfizer’s new IBRANCE approval boosts its oncology prospects, while the CFO exit to Nike signals a strategic shift—what this means for investors and growth.

Pfizer’s new oncology wins: 7‑year CROWN data shows LORBRENA beats standard care, TALAPRO‑3 reduces prostate cancer progression, and a $10.5 b partnership with Innovent boosts China reach and future earnings.